Pharma: Wohl doch keine Fusionsgespräche zwischen Astra Zeneca und BMS
Entgegen anderslautender Meldungen laufen derzeit keine Verhandlungen zwischen den beiden Pharmakonzernen. Analysten hatten bereits Zweifel angemeldet.
London and New York — Reports indicate there are no discussions ongoing between pharmaceutical giants Astra Zeneca and Bristol Myers Squibb about a potential mega-merger. According to a senior source familiar with the matter, Reuters reported on Wednesday that "there is no agreement between AstraZeneca and BMS, and no business was ever on the table.
There are no discussions between the companies." Both firms declined to comment on the matter. Reuters had initially reported on Sunday that the two pharmaceutical manufacturers had begun initial talks about a possible partnership. The newspaper "Financial Times" had also covered the alleged approach. The speculation had put pressure on Astra Zeneca's shares, which subsequently fell by around nine percent. Bristol Myers Squibb's shares, however, remained largely stable.
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
